The VeriStrat test, originally developed for prediction of benefit from EGFR-TKIs in NSCLC, has been validated in numerous independent studies, demonstrating strong predictive [48,53] and prognostic [54,55,56] properties in various settings. This evidence concerns the gene EGFR and non-small cell lung carcinoma.